ReShape Lifesciences (RSLS) Registration Filing summary

Company overview and business model

• Focuses on physician-led weight-loss solutions, offering FDA-approved Lap-Band systems and developing minimally invasive treatments for obesity and metabolic disease.

• Portfolio includes Lap-Band 2.0 FLEX, ReShape Obalon Balloon, and a neuromodulation device for type 2 diabetes.

• Pursues growth through disciplined operations, product innovation, and evidence-based care, with global expansion and strategic partnerships.

Financial performance and metrics

• For the year ended December 31, 2024, reported $8.0 million in revenue and a net loss of $7.1 million.

• Operating expenses decreased by approximately 43% in 2024 compared to the prior year, excluding one-time costs.

• As of December 31, 2024, had $0.7 million in cash and cash equivalents and a working capital deficit of $0.1 million.

• Accumulated deficit of $642.7 million as of year-end 2024.

• Auditors expressed substantial doubt about the ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.

• Recent asset sale to Biorad for $2.25 million in cash, with proceeds allocated to transaction costs, employee costs, and preferred shareholder payouts.